More on NVCT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-6.7% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Nuvectis Pharma (NQ:NVCT)
Delayed: 19.54 +0.23 (1.19%)
Prev. Close $19.31  
Open$19.37 
52 Wk High$ 
52 Wk Low$ 
Day High$20.00 
Day Low$19.01 
P/E N/A  
EPS$ 
Volume146,607 


Jul 23, 2026 09:00 AM Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Jul 23, 2026 07:30 AM China approves Nuvectis drug ciprocopan for PNH treatment
Jul 23, 2026 07:30 AM Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Jul 14, 2026 10:42 AM StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
Jul 1, 2026 01:42 PM Form 4 Nuvectis Pharma, Inc. For: Jun 30 Filed by: Mosseri Marlio Charles
Jul 1, 2026 01:40 PM Form 4 Nuvectis Pharma, Inc. For: Jun 30 Filed by: BENTSUR RON
Jun 30, 2026 04:43 PM Form 8-K Nuvectis Pharma, Inc. For: Jun 29
Jun 30, 2026 04:42 PM Form 424B5 Nuvectis Pharma, Inc.
Jun 29, 2026 10:30 PM Nuvectis Pharma prices $100M public offering at $20 per share
Jun 29, 2026 10:30 PM Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
View All Articles

Entities mentioned with NVCT

View All Entities